Last reviewed · How we verify
GC3110A
GC3110A is a small molecule that targets the SGLT2 receptor.
GC3110A is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | GC3110A |
|---|---|
| Sponsor | Green Cross Corporation |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
GC3110A works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in patients with type 2 diabetes. By reducing glucose reabsorption, GC3110A also has a mild diuretic effect, which can help to reduce blood pressure.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age (PHASE3)
- A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older (PHASE3)
- A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children (PHASE3)
- A Multicenter, Double-blind, Parallel Phase III Study (PHASE3)
- A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC3110A CI brief — competitive landscape report
- GC3110A updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI